Allan Camaisa

Chief Executive Officer
Chairman of the Board of Directors

As an innovator for over 25 years, Allan Camaisa is an extraordinarily successful entrepreneur, investor, and technologist who brings state-of-the-art software application and system solutions and services to healthcare organizations, government agencies, and commercial enterprises. He has been a founder of several successful enterprises and brought measurable C-level executive leadership to start-up companies struggling to achieve operational success which required extensive turnaround and repositioning strategies.

Mr. Camaisa is the current Chief Executive Officer (CEO) of Calidi Biotherapeutics and oversees execution of the Calidi Biotherapeutics business and financial operations. Calidi Biotherapeutics mission is to eradicate difficult to treat cancers. Calidi Biotherapeutics patented technology enables patients to undergo treatment with none of the well-known debilitating side effects associated with traditional cancer treatments such as hair loss, appetite loss, weight loss, nausea, harm to healthy living tissue and other detrimental health concerns. The Calidi Biotherapeutics approach leverages a patient’s own cells, bundled with a proprietary anti-cancer payload which is then targeted directly at tumorous cells while sparing the patient’s healthy cells to allow the patient’s immune system to fight and ultimately kill the cancer cells.

Previously Mr. Camaisa was the CEO and Chairman of Parallel6, Inc., whose digital mobile software platform engaged clinical trial participants, and powered the enrollment, engagement, management, and retention of those participants on behalf of pharmaceutical organizations. Parallel6 was sold to PRA Health Sciences (NASDAQ:PRAH) in Q2 of 2017. Mr. Camaisa was also instrumental in providing the company’s Series A funding. Some of their clients included, Sanofi, STSI/Genentech, Thermal Fisher, Johnson & Johnson/Janssen, Abbott/Abbvie, PPD, PRA Health, Pfizer, Roche, and the NIH, among others.

Mr. Camaisa previously founded AnakamTM, Inc., a software security company, also focused on healthcare, which safeguarded medical records online through a platform delivering NIST Level 3 multifactor authentication and security. Anakam sold over 5 million licenses to the Veterans Administration (VA) for deployment across 250 global locations, to the Center for Medicare and Medicaid, to the Department of Homeland Security and to medical device companies such as Boston Scientific and EntraHealth. Anakam was recognized by INC 500 as one of the fastest growing companies in the U.S. Equifax, Inc (NYSE:EFX) subsequently acquired Anakam in 2010.

Preceding Anakam™, Mr. Camaisa’s High Technology Solutions TM (HTS), a software systems integrator with over $50 million in revenues which was recognized as an INC 500 company three years in a row. Mr. Camaisa led HTS from a small, two-person company to one with 500+ employees across the US. HTS was sold to Wireless Facilities, Inc., now Kratos Defense (NASDAQ:KTOS) in 2004.

Mr. Camaisa successfully raised $17 million funding in 1999 from GE Capital, Intel, Ford Motor Company, and JP Morgan Chase Hambrecht & Quist to launch an Internet company, Eye Velocity, that focused on Internet Visualization.

Mr. Camaisa owns 7 U.S. patents and has received various awards from Tech America, the U.S. Small Business Association, the Asian Business Association and Deloitte FAST 50. He has been recognized and honored with the Governor’s Small Business of the Year Award, the 1998 Ernst and Young Regional Entrepreneur of the Year in the Internet and Software Category and as the SBA Small Business Person of the Year.

He is a graduate of both the United States Naval Academy and the prestigious Owners Management Program at Harvard Business School.

Mr. Camaisa enthusiastically serves as member of YPO (Young Presidents Organization) San Diego Coastal Chapter as he has on several other volunteer boards including the United Way of San Diego and Opportunity International (Micro-Enterprise Loans to the Poor).